{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:39:32Z","timestamp":1792575572533,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The frequency and clinical phenotypes of cardiotoxic events in chimeric antigen receptor (CAR) T-cell recipients remain poorly understood given that landmark approval trials typically exclude patients with high-risk cardiovascular profiles and data from nontrial settings are scarce.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To summarize the prevalence of adverse cardiovascular events among adults receiving CAR T-cell therapies for advanced hematologic malignant neoplasms.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n MEDLINE, Embase, Cochrane Library, and Google Scholar were systematically searched from database inception until February 26, 2024.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Observational studies were included if they comprised adult CAR T-cell recipients with advanced hematologic malignant neoplasms and if they systematically evaluated cardiovascular complications.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n \n Extraction of prespecified parameters related to the patient population, study design, and clinical events was performed at the study level by 2 independent reviewers in accordance with the Meta-Analysis of Observational Studies in Epidemiology (\n MOOSE<\/jats:ext-link>\n ) reporting guideline. Meta-analysis of single proportions was conducted using random-effect models with Freeman-Tukey double arcsine transformations to calculate pooled prevalence estimates. Sensitivity analysis was performed using generalized linear mixed models with logit transformations.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Ventricular and supraventricular arrhythmias, heart failure events, reduction in left ventricular ejection fraction, myocardial infarction, and cardiovascular and all-cause mortality.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Thirteen studies comprising 1528 CAR T-cell recipients (median [IQR] age, 61 [58.7-63.0] years; 1016 males [66%]; 80% patients with lymphoma) were included. The median (IQR) duration of follow-up was 487 (294-530) days. On random-effects meta-analysis, we observed a pooled prevalence of 0.66% (95% CI, 0.00%-2.28%) for ventricular arrhythmia, 7.79% (95% CI, 4.87%-11.27%) for supraventricular arrhythmia, 8.68% (95% CI, 2.26%-17.97%) for left ventricular dysfunction, 3.87% (95% CI, 1.77%-6.62%) for heart failure events, 0.62% (95% CI, 0.02%-1.74%) for myocardial infarction, and 0.63% (95% CI, 0.13%-1.38%) for cardiovascular death. The pooled prevalence of all-cause mortality was 30.01% (95% CI, 19.49%-41.68%). Sensitivity analyses generated similar findings.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This meta-analysis found a low prevalence of ventricular arrhythmia, myocardial infarction, and cardiovascular death among CAR T-cell recipients over a short-term to midterm follow-up. Left ventricular dysfunction and supraventricular arrhythmia were the most commonly reported cardiovascular complications, suggesting that cardiovascular surveillance strategies should focus on decreases in ejection fraction and supraventricular arrhythmia.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.37222","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T11:01:08Z","timestamp":1728298868000},"page":"e2437222","source":"Crossref","is-referenced-by-count":35,"title":["Cardiovascular Events After Chimeric Antigen Receptor T-Cell Therapy for Advanced Hematologic Malignant Neoplasms"],"prefix":"10.1001","volume":"7","author":[{"given":"David","family":"Koeckerling","sequence":"first","affiliation":[{"name":"Department of Cardiology, Angiology and Respiratory Medicine, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), partner site, Mannheim\/Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohin K.","family":"Reddy","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, United Kingdom"},{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Barker","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Eichhorn","sequence":"additional","affiliation":[{"name":"Division of Acute Medicine, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pip","family":"Divall","sequence":"additional","affiliation":[{"name":"University Hospitals of Leicester National Health Service Trust, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Howard","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Korell","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology & Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology & Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology & Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Frey","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology and Respiratory Medicine, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), partner site, Mannheim\/Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz H.","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology and Respiratory Medicine, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), partner site, Mannheim\/Heidelberg, Germany"},{"name":"German Cancer Research Centre (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"issue":"20","key":"zoi241085r1","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","article-title":"Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.","volume":"43","author":"Totzeck","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"zoi241085r2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-cell antineoplastic therapies: JACC: CardioOncology primer.","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"1","key":"zoi241085r3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"6576","key":"zoi241085r4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury.","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"1","key":"zoi241085r5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi241085r6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"26","key":"zoi241085r7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10343","key":"zoi241085r8","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"zoi241085r9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","article-title":"MOOSE reporting guidelines for meta-analyses of observational studies.","volume":"156","author":"Brooke","year":"2021","journal-title":"JAMA Surg"},{"issue":"18","key":"zoi241085r10","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy.","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"zoi241085r11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.15171\/ijhpm.2014.71","article-title":"The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence.","volume":"3","author":"Munn","year":"2014","journal-title":"Int J Health Policy Manag"},{"key":"zoi241085r12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jclinepi.2020.06.039","article-title":"Quality assessment of prevalence studies: a systematic review.","volume":"127","author":"Migliavaca","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"zoi241085r13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root.","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann Math Stat"},{"issue":"11","key":"zoi241085r14","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence.","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"issue":"1","key":"zoi241085r15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12874-021-01381-z","article-title":"Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence.","volume":"21","author":"Barker","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"zoi241085r16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jrsm.1348","article-title":"Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions.","volume":"10","author":"Schwarzer","year":"2019","journal-title":"Res Synth Methods"},{"issue":"4","key":"zoi241085r17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis.","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"Int J Evid Based Healthc"},{"issue":"25","key":"zoi241085r18","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T).","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"zoi241085r19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002303","article-title":"Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.","volume":"9","author":"Brammer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"17","key":"zoi241085r20","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy\u2013associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma.","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"zoi241085r21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2991\/chi.k.210718.001","article-title":"High sensitivity troponin T and NT-proBNP in patients receiving chimeric antigen receptor (CAR) T-cell therapy.","volume":"3","author":"Hu","year":"2021","journal-title":"Clin Hematol Int"},{"key":"zoi241085r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102504","article-title":"Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study.","volume":"69","author":"Korell","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"16","key":"zoi241085r23","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/bloodadvances.2023009766","article-title":"Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.","volume":"7","author":"Lee","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"zoi241085r24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40959-023-00170-5","article-title":"Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study.","volume":"9","author":"Lee","year":"2023","journal-title":"Cardiooncology"},{"issue":"6","key":"zoi241085r25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaccao.2023.07.009","article-title":"Incidence of MACE in patients treated with CAR-T cell therapy: a prospective study.","volume":"5","author":"Lefebvre","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"2","key":"zoi241085r26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy: a retrospective study.","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"22","key":"zoi241085r27","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","article-title":"Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.","volume":"44","author":"Mahmood","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"zoi241085r28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/ejh.14088","article-title":"Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T-cell therapy.","volume":"112","author":"Patel","year":"2024","journal-title":"Eur J Haematol"},{"key":"zoi241085r29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.691064","article-title":"An analysis of cardiac disorders associated with chimeric antigen receptor T cell therapy in 126 patients: a single-centre retrospective study.","volume":"11","author":"Qi","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"zoi241085r30","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3324\/haematol.2021.280009","article-title":"Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma.","volume":"107","author":"Steiner","year":"2022","journal-title":"Haematologica"},{"issue":"6","key":"zoi241085r31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"issue":"6","key":"zoi241085r32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1200\/OP.22.00713","article-title":"Cardiotoxicities of novel therapies in hematologic malignancies: chimeric antigen receptor T-cell therapy and bispecific T-cell engager therapy.","volume":"19","author":"Marar","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"12","key":"zoi241085r33","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity.","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am J Cardiol"},{"issue":"6","key":"zoi241085r34","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s10238-023-01042-z","article-title":"Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis.","volume":"23","author":"Guo","year":"2023","journal-title":"Clin Exp Med"},{"key":"zoi241085r35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.924208","article-title":"Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: a meta-analysis.","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2824532\/koeckerling_2024_oi_241085_1727711976.9767.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T11:01:09Z","timestamp":1728298869000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2824532"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.37222","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]}}}